TMPRSS2-ERG融合基因在国人前列腺癌组织中的表达及其临床意义

发布时间：2018-01-29 08:42

本文关键词： 前列腺肿瘤融合基因内分泌疗法预后　出处：《中国男科学杂志》2016年12期 　论文类型：期刊论文

【摘要】：目的探讨TMPRSS2-ERG融合基因在中国人群前列腺癌中的发生率以及其临床病理特征和对内分泌治疗的预后价值。方法收集2010年10月到2014年12月前列腺癌穿刺活检标本96例及病例临床病理资料。所有患者均接受内分泌治疗。利用荧光原位杂交技术检测标本中TMPRRS2-ERG融合基因。比较融合基因阳性和阴性患者的临床病理资料分布及预后差异。结果患者年龄范围为51~93岁,中位年龄为77岁;PSA范围为5.0-5000.0ng/m L。Gleason评分7分的有6例(6.3%),Gleason评分=7分的有38例(39.6%),Gleason评分7分的有52例(54.2%)。临床分期T1-T2有32例,T3-T4有64例;M0为35例,M1为61例。穿刺标本TMPRSS2-ERG阳性有19例(19.8%)。缺失型重排有11例,易位型重排亦有11例,同时含有缺失型和易位型重排患者共3例。融合基因阳性和阴性患者在年龄、PSA、Gleason评分、主要Gleason分级、T分期及M分期的临床分布及内分泌治疗预后方面差异均不具有统计学意义(P0.05)。结论中国人群的前列腺癌TMPRSS2-ERG融合基因的发生率与日韩等亚洲国家人群基本一致,约为20%,远低于欧美人群。TMPRSS2-ERG融合基因阳性和阴性患者的年龄、治疗前PSA水平、Gleason评分、主要Gleason分级以及临床分期的分布不存在差异,同时其对内分泌治疗患者的预后不具备预测价值。
[Abstract]:Objective to investigate the incidence of TMPRSS2-ERG fusion gene in prostate cancer in Chinese population, its clinicopathological features and prognostic value in endocrine therapy. In December, 14 years, 96 prostate cancer biopsy specimens and clinicopathological data were collected. All patients received endocrine therapy. Fluorescence in situ hybridization was used to detect TMPRRS2-ERG fusion. Gene. To compare the distribution of clinicopathological data and prognosis between positive and negative patients with fusion gene. Results the age range of the patients was 51 ~ 93 years old. The median age was 77 years; The PSA ranges from 5.0-5000.0ng / m L Gleason score 7 to 6.3Gleason score = 7 in 38 patients with Gleason score = 7. There were 52 cases with Gleason score of 7, 32 cases with T1-T2 and 64 cases with T3-T4. M _ 0 was 35 cases of M _ 1 and 61 cases of M _ (1). There were 19 cases of TMPRSS2-ERG positive in puncture specimens, 11 cases of deletion type rearrangement and 11 cases of translocation type rearrangement. There were 3 patients with deletion and translocation rearrangement. The patients with positive and negative fusion gene had Gleason score and main Gleason grade at age. There was no significant difference in the clinical distribution and the prognosis of endocrine therapy between T stage and M stage (P 0.05). Conclusion the incidence of prostate cancer TMPRSS2-ERG fusion gene in Chinese population is similar to that in Asian countries such as Japan and Korea. The age of the patients with positive and negative fusion gene of TMPRSS2-ERG was much lower than that of the patients with positive or negative fusion gene of TMPRSS2-ERG. The level of PSA before treatment was significantly lower than that of the patients with Gleason score. There was no difference in the distribution of major Gleason grades and clinical stages, and the prognosis of patients with endocrine therapy was not predicted.
【作者单位】：华东医院泌尿外科;华东医院病理科;
【分类号】：R737.25
【正文快照】： 前列腺癌是男性常见的恶性肿瘤,据统计,前列腺癌的肿瘤发病率在世界范围内位居第二位,其中在欧美国家高居第一位[1]。近年来我国前列腺癌发病率明显呈现上升趋势,在北京、上海、广州三城市均已超过男性膀胱癌的发病率,居男性泌尿生殖系肿瘤发病率第一位[2]。自2005年Tomlin等

【参考文献】